Company news

Edding Genor Group Holdings Limited news in 2026

Edding Genor Group Holdings Limited's news releases, calls and decks from 2026, newest first.

View company

Next Day Disclosure Return

November 18, 2026

Continuing connected transactions and connected transaction in relation to (1) technology transfer and commercial production; and (2) equipment buyback

November 17, 2026

Next Day Disclosure Return

November 17, 2026

Next Day Disclosure Return

November 16, 2026

Voluntary announcement - IND approvals of GB268 from the NMPA for Phase Ib/II clinical trial in NSCLC and Phase II/iii clinical trial in BTC

November 16, 2026

Next Day Disclosure Return

November 13, 2026

Next Day Disclosure Return

November 12, 2026

Next Day Disclosure Return

November 11, 2026

Next Day Disclosure Return

November 10, 2026

Next Day Disclosure Return

November 9, 2026

Next Day Disclosure Return

November 6, 2026

Next Day Disclosure Return

November 4, 2026

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026

November 4, 2026

Next Day Disclosure Return

November 3, 2026

Next Day Disclosure Return

November 2, 2026

Next Day Disclosure Return

October 30, 2026

Next Day Disclosure Return

October 28, 2026

Next Day Disclosure Return

October 27, 2026

Voluntary announcement - first-in-human Phase I study data of GB268 presented at the esmo congress 2026

October 23, 2026

Next Day Disclosure Return

October 23, 2026

Next Day Disclosure Return

October 21, 2026

Next Day Disclosure Return

October 20, 2026

Next Day Disclosure Return

October 14, 2026

Next Day Disclosure Return

October 12, 2026

Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer

October 11, 2026

Next Day Disclosure Return

October 8, 2026

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026

October 7, 2026

Next Day Disclosure Return

September 30, 2026

Next Day Disclosure Return

September 29, 2026

Next Day Disclosure Return

September 28, 2026

2026 Interim Report

September 28, 2026

EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA

July 2, 2026

Edding Genor Group Holdings: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial

February 8, 2026